Nuvo Pharmaceuticals Revenue, Profits - NRIFF Annual Income Statement

Add to My Stocks
$2.04 $0 (0%) NRIFF stock closing price Sep 18, 2018 (Closing)

Financial analysis of Nuvo Pharmaceuticals involves more than just checking the Nuvo Pharmaceuticals stock price, by looking at the financial statements of the company in detail. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 20.41M to 13.51M and how operating and non operating activities have impacted the NRIFF stock. One also needs to look at Nuvo Pharmaceuticals assets, operating expenses and Nuvo Pharmaceuticals free cash flow. The Nuvo Pharmaceuticals profit and loss statement shows revenue of $13.51M for 2017. Revenue has decreased by -33.81% YOY for NRIFF stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Nuvo Pharmaceuticals Revenues or Net Sales
13.51M20.41M16.73M11.83M4.3M8.94M9.05M
Cost Of Goods Sold (COGS)6.25M8.57M8.05M5.01M4.63M7.27M7.35M
Nuvo Pharmaceuticals Gross Profit
7.25M11.84M8.67M6.81M-0.32M1.66M1.69M
Research & Development Expense-1.07M8.09M7.29M6.82M6.85M7.41M
Selling General & Admin Expense5.49M5.04M7.28M11.75M9.82M14.02M11.75M
Income Before Depreciation Depletion Amortization1.32M5.73M-6.69M-12.24M-16.98M-19.21M-17.46M
Depreciation Depletion Amortization-------
Non Operating Income-0.1M-0.13M1.15M47.87M7.64M6.22M9.78M
Interest Expense-------
Nuvo Pharmaceuticals Pretax Income
1.22M5.59M-5.57M34.98M-9.96M-13.37M-7.69M
Provision for Income Taxes-------
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations1.21M5.59M-5.57M34.96M-10.08M-13.57M-7.8M
Extraordinary Items & Discontinued Operations--2.4M-----
Nuvo Pharmaceuticals Profit/ Loss (Net Income)
1.21M3.19M-5.57M34.96M-10.08M-13.57M-7.8M
Average Shares used to compute Diluted EPS11.72M11.71M10.95M10.27M8.81M8.52M-
Average Shares used to compute Basic EPS11.55M11.46M10.95M10.02M8.81M8.52M-
Income Before Nonrecurring Items1.22M5.59M-5.58M-12.09M-3.91M-1.7M-
Income from Nonrecurring Items---46.07M-6.18M-11.88M-
Nuvo Pharmaceuticals Earnings Per Share Basic Net
0.110.28-0.513.39-1.15-1.33-
Nuvo Pharmaceuticals Earnings Per Share Diluted Net
0.090.27-0.513.31-1.15-1.33-
EPS Diluted Before Nonrecurring Items0.090.48-0.51-1.33-0.450.00-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Novartis financial analysis

The key things to look for in an income statement while doing Nuvo Pharmaceuticals stock analysis are:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Nuvo Pharmaceuticals revenue chart implies that the company is growing. It has not been the case with Nuvo Pharmaceuticals. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $1.21M for Nuvo Pharmaceuticals for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the NRIFF income statement, one can check the Nuvo Pharmaceuticals historical stock prices to check how the price has moved with time.

Nuvo Pharmaceuticals Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
104.55
PS Ratio (price sales ratio)
1.71
Operating Margin
0
Net Profit Margin
18
Dividend Yield
0%

Annual Income Statements - NUVO PHARMACEUTICA COM NPV Industry Peers

Cardax income statement, CITIUS PHARMACT income statement, NovaBay Pharma income statement, Novartis income statement